Commerzbank Ag Analysts Give Bayer AG (BAYN) a €124.00 Price Target
Commerzbank Ag set a €124.00 ($144.19) price objective on Bayer AG (FRA:BAYN) in a research report sent to investors on Wednesday. The brokerage currently has a buy rating on the healthcare company’s stock.
Several other equities research analysts have also weighed in on the stock. J P Morgan Chase & Co reaffirmed a buy rating on shares of Bayer AG in a report on Wednesday, September 13th. Goldman Sachs Group, Inc. (The) set a €125.00 ($145.35) target price on shares of Bayer AG and gave the stock a buy rating in a report on Monday, July 24th. Sanford C. Bernstein set a €126.00 ($146.51) target price on shares of Bayer AG and gave the stock a buy rating in a report on Tuesday, September 5th. Nord/LB set a €106.00 ($123.26) price objective on shares of Bayer AG and gave the stock a neutral rating in a report on Friday, July 28th. Finally, Baader Bank set a €140.00 ($162.79) price objective on shares of Bayer AG and gave the stock a buy rating in a report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the company. The company has an average rating of Buy and an average price target of €122.43 ($142.36).
Shares of Bayer AG (BAYN) opened at €107.55 ($125.06) on Wednesday. Bayer AG has a fifty-two week low of €86.06 ($100.07) and a fifty-two week high of €123.82 ($143.98).
Bayer AG Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Stock Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related stocks with our FREE daily email newsletter.